Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

North
23 April 2014 16:28


Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Sales Director
claire@zenopa.com
+44 1494 818025

Testimonials
Zenopa is easily the best recruitment agency I have ever used. Extremely efficient and friendly staff with a huge number of clients and potential job offerings.
Chloe, 2013

UCB and Otsuka to focus collaboration on CNS disorders

13 January 2012 00:00 in Pharmaceutical Company Product News


UCB has announced that it will be amending the scope of its collaborative partnership with Otsuka Pharmaceutical, in order to focus solely on central nervous system (CNS) disorders.

Under the terms of the reorganised alliance, the companies will be discontinuing their joint work in the field of immunology, which links in with Otsuka's decision to focus its future operations on CNS disorders and oncology.

As a result of this, UCB will be continuing with the further development of its immunology pipeline in Japan independently, commencing with plans to launch its drug Cimzia in the Asian nation.

The companies stated that they remain dedicated to continuing their CNS drug development, with products such as the anti-epileptic drug E Keppra and the dopamine agonist rotigotine.

Mark McDade, executive vice-president and chief operating officer for UCB, said: "We are happy to continue our successful partnership with Otsuka Pharmaceutical in the area of CNS."

Last month, UCB announced the commencement of a new clinical study of Cimzia, which will evaluate the drug's short and long-term performance compared to a leading alternative.ADNFCR-8000103-ID-801263654-ADNFCR

Other news stories from 13/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd